The effects of 48 weeks of rosiglitazone on hepatocyte mitochondria in human nonalcoholic steatohepatitis

Hepatology

Volumn 46, Issue 4, 2007, Pages 1101-1107

  Caldwell, Stephen H ^a,d   Patrie, James T ^b   Brunt, Elizabeth M ^c   Redick, Jan A ^a   Davis, Christine A ^a   Park, Sang H ^a   Neuschwander Tetri, Brent A ^c  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

^c Saint Louis University   (United States)

^d UNIVERSITY OF VIRGINIA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ROSIGLITAZONE;

APOPTOSIS; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; ENDOPLASMIC RETICULUM; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER CELL; MITOCHONDRION; NONALCOHOLIC FATTY LIVER; PRIORITY JOURNAL;

ADULT; BIOPSY; DOSE-RESPONSE RELATIONSHIP, DRUG; ENERGY METABOLISM; FATTY LIVER; FEMALE; HEPATOCYTES; HUMANS; HYPOGLYCEMIC AGENTS; INCLUSION BODIES; LIVER; MALE; MITOCHONDRIA, LIVER; PROSPECTIVE STUDIES; THIAZOLIDINEDIONES;

EID: 36348938829     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.21813     Document Type: Article

References (41)

1. Dianzani MU. The content of adenosine polyphosphates in fatty livers. Biochem J 1957;65:116-124.
2. Pessayre D, Fromenty B. NASH: a mitochondrial disease. J Hepatol 2005;42:928-940.
3. Cortez-Pinto H, Chatham J, Chacko VP, Arnold C, Rashid A, Diehl AM. Alterations in liver ATP homeostasis in human nonalcoholic steatohepatitis: a pilot study. JAMA 1999;282:1659-1664.
4. Perez-Carrera M, Del Hoyo P, Martin MA, Rubio JC, Martin A, Castellano G, et al. Defective hepatic mitochondrial respiratory chain in patients with nonalcoholic steatohepatitis. HEPATOLOGY 2003;38:999-1007.
5. Baffy G. Uncoupling protein-2 and non-alcoholic fatty liver disease. Front Biosci 2005;10:2082-2096.
6. Sternlieb I, Berger JE. Optical diffraction studies of crystalline structures in electron micrographs. J Cell Biol 1969;43:448-455.
7. Caldwell SH, Swerdlow RH, Khan EM, Iezzoni JC, Hespenheide EE, Parks JK, et al. Mitochondrial abnormalities in non-alcoholic steatohepatitis. J Hepatol 1999;31:430-434.
8. Chedid A, Mendenhall CL, Tosch T, Chen T, Rabin L, Garcia-Pont P, et al. Significance of megamitochondria in alcoholic liver disease. Gastroenterology 1986;90:1858-1864.
9. Caldwell SH, Chang CY, Nakamoto RK, Krugner-Higby, L. Mitochondria in nonalcoholic fatty liver disease. Clin Liver Dis 2004;8:595-617.
10. Sanyal AJ, Campbell-Sargent C, Mirshani F, Rizzo WB, Contos MJ, Sterling RK, et al. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology 2001;120:1183-1192.
11. Le TH, Caldwell SH, Redick JA, Sheppard BL, Davis CA, Arseneau K, et al. The lobular disrribution of mitochondrial abnormalities in NASH. HEPATOLOGY 2004;39:1423-1429.
12. Fajas L, Auboeuf D, Raspe E, Schoonjans K, Lefebvre A-M, Saladin R, et al. The organization, promoter analysis, and expression of the human PPAR-γ gene. J Biol Chem 1997;272:18779-18789.
13. Law RE, Goetze S, Xi X-P, Jackson S, Kawano Y, Demer L, et al. Expression and function of PPARγ in rat and human vascular smooth muscle cells. Circulation 2000;101:1311-1318.
14. Roberts AW, Thomas A, Rees A, Evans M. Peroxisome proliferator-activated receptor-gamma agonists in atherosclerosis: current evidence and future directions. Curr Opin Lipidol 2003;14:567-573.
15. Caldwell SH, Argo CK, Al-Osaimi AM. Therapy of NAFLD: insulin sensitizing agents. J Clin Gastroenterol 2006;40(Suppl 1):S61-S66.
16. Belfort R, Harrison SA, Brown K, Darland C, Finch J, Hardies J, et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med 2006;355:2297-2307.
17. McCullough AJ. Thiazolidinediones for nonalcoholic steatohepatitis - promising but not ready for prime time. N Engl J Med 2006;355:2361-2363.
18. Tiikkainen M, Hakkinen A-M, Korsheninnikova E, Nyman T, Makimattila S, Yki-Jarvinen H. Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes. Diabetes 2004;53:2169-2176.
19. Shadid S, Jensen MD. Effects of pioglitazone versus diet and exercise on metabolic health and fat distribution in upper body obesity. Diabetes Care 2003;26:3148-3152.
20. Wilson-Frirch L, Nicoloro S, Chouinard M, Lazar MA, Chui PC, Leszyk J, et al. Mitochondrial remodeling in adipose tissue associated with obesity and treatment with rosiglitazone. J Clin Invest 2004;114:1281-1289.
21. Laplante M, Festuccia WT, Soucy G, Gelinas Y, Lalonde J, Berger JP, et al. Mechanisms of the depot specificity of peroxisome proliferator-activated receptor γ action on adipose tissue metabolism. Diabetes 2006;55:2771-2778.
22. Neuschwander-Tetri BA, Brunt EM, Wehmeier KR, Oliver D, Bacon BR. Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-γ ligand rosiglitazone. HEPATOLOGY 2003;38:1008-1017.
23. Arias IM. The hepatocyte organization. In: Arias IM, Jacoby WB, Popper H, Schachter D, Shafritz DA, eds. The Liver: Biology and Pathobiology. 2nd ed. New York, NY: Raven Press; 1988:9.
24. Ikura Y, Ohsawa M, Suekane T, Fukushima H, Itabe H, Jomura H, et al. Localization of oxidized phosphatidylcholine in nonalcoholic fatty liver disease: impact on disease progression. HEPATOLOGY 2006;43:506-514.
25. Caldwell SH, Redick JA, Chang CY, Davis CA, Argo CK, Al Osaimi AM. Enlarged hepatocytes in NAFLD examined with osmium fixation: does microsteatosis underlie cellular ballooning in NASH? Am J Gastroenterol 2006;101:1677-1678.
26. Feldstein AE, Canby A, Angulo P, Taniai M, Burgart LJ, Lindor KD, et al. Hepatocyte apoptosis and FAS expression are prominent features of human nonalcoholic steatohepatitis. Gastroenterology 2003;125:437-443.
27. Rashid A, Wu T-C, Huang C-C, Chen C-H, Lin HZ, Yang SQ, et al. Mitochondrial proteins that regulate apoptosis and necrosis are induced in mouse fatty liver. HEPATOLOGY 1999;29:1131-1138.
28. Caldwell SH, Hespenheide EE, Redick JA, Iezzoni JC, Battle EH, Sheppard BL. A pilot study of a thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis. Am J Gastroenterol 2001;96:519-525.
29. Oliveira CP, Coelho AM, Barbeiro HV, Lima VM, Soriano F, Ribeiro C, et al. Liver mitochondrial dysfunction and oxidative stress in the pathogenesis of experimental nonalcoholic fatty liver disease. Braz J Med Biol Res 2006;39:189-194.
30. Brunmair B, Staniek K, Gras F, Scharf N, Althaym A, Clara R, et al. Thiazolidinediones, like metformin, inhibit respiratory complex I: a common mechanism contributing to their antidiabetic actions? Diabetes 2004;53:1052-1059.
31. Van Huyen JP, Batisse D, Heudes D, Belair MF, Piketty C, Gonzalez-Canali G, et al. Alteration of cytochrome oxidase subunit I labeling is associated with severe mitochondriopathy in NRTI-related hepatotoxicity in HIV patients. Mod Pathol 2006;19:1277-1288.
32. Smith SR, De Jonge L, Volaufova J, Li Y, Xie H, Bray GA. Effect of pioglitazone on body composition and energy expenditure: a randomized controlled trial. Metabolism 2005;54:24-32.
33. Laplante M, Festuccia WT, Soucy G, Gelinas Y, Lalonde J, Berger JP, et al. Mechanisms of the depot specificity of peroxisome proliferator-activated receptor gamma action on adipose tissue metabolism. Diabetes 2006;55:2771-2778.
34. Bogacka I, Ukropcova B, McNeil M, Gimble JM, Smith SR. Structural and functional consequences of mitochondrial biogenesis in human adipocytes in vivo. J Clin Endocrinol Metab 2005;90:6650-6656.
35. Bogacka I, Xie H, Bray GA, Smith SR. Pioglitazone induces mitochondrial biogenesis in human subcutaneous adipose tissue in vivo. Diabetes 2005;54:1392-1399.
36. LeBrasseur NK, Kelly M, Tsao TS, Farmer SR, Saha AK, Ruderman NB, et al. Thiazolidinediones can rapidly activate AMP-activated protein kinase in mammalian tissues. Am J Physiol Endocrinol Merab 2006;291:E175-E181.
37. Saha AK, Avilucea PR, Ye JM, Assifi MM, Kraegen EW, Ruderman NB. Pioglitazone treatment activates AMP-activated protein kinase in rat liver and adipose tissue in vivo. Biochem Biophys Res Commun 2004;314:580-585.
38. Lutchman G, Promrat K, Kleiner DE, Heller T, Ghany MG, Yanovski JA, et al. Changes in serum adipokine levels during pioglitazone treatment for nonalcoholic steatohepatitis: relationship to histological improvement. Clin Gastroenterol Hepatol 2006;4:1048-1052.
39. Wilson-Fritch L, Nicoloro S, Chouinard M, Lazar MA, Chui PC, Leszyk J, et al. Mitochondrial remodeling in adipose tissue associated with obesity and treatment with rosiglitazone. J Clin Invest 2004;114:1281-1299.
40. Chavin KD, Yang S, Lin HZ, Chatham J, Chacko VP, Hoek JB, et al. Obesity induces expression of uncoupling protein-2 in hepatocytes and promotes liver ATP depletion. J Biol Chem 1999;274:5692-5700.
41. Schadinger SE, Bucher NL, Schreiber BM, Farmer SR. PPARgamma2 regulates lipogenesis and lipid accumulation in steatotic hepatocytes. Am J Physiol Endocrinol Metab 2005;288:E1195-E1205.